These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 3304210)

  • 21. Hormesis [biological effects of low-level exposure (B.E.L.L.E.)] and dermatology.
    Thong HY; Maibach HI
    Cutan Ocul Toxicol; 2007; 26(4):329-41. PubMed ID: 18058307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug distribution and effect.
    Curry SH
    J R Coll Physicians Lond; 1970 Jul; 4(4):315-34. PubMed ID: 4948351
    [No Abstract]   [Full Text] [Related]  

  • 25. Toxicology and carcinogenesis studies of 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (CAS No. 31508-00-6) in female harlan Sprague-Dawley rats (gavage studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 2010 Nov; (559):1-174. PubMed ID: 21383778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of safety/risk of chemicals: inception and evolution of the ADI and dose-response modeling procedures.
    Lu FC; Sielken RL
    Toxicol Lett; 1991 Dec; 59(1-3):5-40. PubMed ID: 1755034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future of toxicology--low-dose toxicology and risk--benefit analysis.
    Rietjens IM; Alink GM
    Chem Res Toxicol; 2006 Aug; 19(8):977-81. PubMed ID: 16918235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prioritization of pharmaceuticals for potential environmental hazard through leveraging a large-scale mammalian pharmacological dataset.
    Berninger JP; LaLone CA; Villeneuve DL; Ankley GT
    Environ Toxicol Chem; 2016 Apr; 35(4):1007-20. PubMed ID: 25772004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic toxicology in the pharmaceutical industry.
    Vanparys P; Marsboom R
    Food Chem Toxicol; 1985 Jan; 23(1):19-22. PubMed ID: 4038678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Carcinogenic risk assessment of chemicals].
    Hayashi Y
    Eisei Shikenjo Hokoku; 1990; (108):1-16. PubMed ID: 1364333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ranking of concern, based on environmental indexes, for pharmaceutical and personal care products: an application to the Spanish case.
    Ortiz de García S; Pinto GP; García-Encina PA; Irusta Mata RI
    J Environ Manage; 2013 Nov; 129():384-97. PubMed ID: 23995140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA.
    WESTON JK; WESTON K
    Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685
    [No Abstract]   [Full Text] [Related]  

  • 34. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the risks of exposures to multiple chemicals with a common mechanism of toxicity: how to cumulate?
    Wilkinson CF; Christoph GR; Julien E; Kelley JM; Kronenberg J; McCarthy J; Reiss R
    Regul Toxicol Pharmacol; 2000 Feb; 31(1):30-43. PubMed ID: 10715222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methodological innovations expand the safety pharmacology horizon.
    Pugsley MK; Curtis MJ
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):59-62. PubMed ID: 22617368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Generally Regarded As Safe.
    Novack GD
    Ocul Surf; 2017 Jan; 15(1):152-155. PubMed ID: 27871773
    [No Abstract]   [Full Text] [Related]  

  • 39. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology.
    Snodin DJ
    Toxicol Lett; 2002 Feb; 127(1-3):161-8. PubMed ID: 12052654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.